SATB2 is expressed in Merkel cell carcinoma

Area of Science:

• Oncology
• Dermatopathology
• Cancer Research

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer.
• Immunohistochemistry typically uses neuroendocrine markers (synaptophysin, chromogranin A) and epithelial markers like cytokeratin 20 (CK20).
• CK20 is a widely used marker for MCC diagnosis.

Purpose of the Study:

• To evaluate the utility of special AT-rich sequence-binding protein 2 (SATB2) as a diagnostic marker for MCC.
• To compare SATB2 expression with established MCC markers (CK20, synaptophysin, chromogranin A).

Main Methods:

• Immunohistochemistry was performed on 20 MCC samples and 51 other skin cancers/neuroendocrine tumors.
• Expression levels of SATB2, CK20, synaptophysin, and chromogranin A were analyzed.
• Results were compared between MCC and other tumor types.

Main Results:

• 95% of MCCs were positive for synaptophysin, 80% for chromogranin A.
• 75% of MCCs showed cytoplasmic CK20 positivity and nuclear SATB2 positivity.
• Two cases showed discordant marker expression.

Conclusions:

• SATB2 is a sensitive and specific immunohistochemical marker for Merkel cell carcinoma.
• SATB2 can serve as an additional diagnostic tool, particularly in challenging cases.
• SATB2 expression is comparable to CK20 in diagnostic utility for MCC.